Alfredo Arias-Cruz

Alfredo Arias-Cruz

Auto-generated profile, based on publicly available information

Alfredo Arias-Cruz

Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
EJEdgardo José Jares
Edgardo José Jares
CBCarlos E. Baena-Cagnani
Carlos E. Baena-Cagnani
MSMario Sánchez-Borges
Mario Sánchez-Borges
LELUIS FELIPE ENSINA
LUIS FELIPE ENSINA
AAAlfredo Arias-Cruz
Alfredo Arias-Cruz
GMGalie Mimessi
Galie Mimessi

1 March 2020 in World Allergy Organization Journal
Verified
Journal Article
Open access
SGSandra Nora Gonzalez-Diaz
Sandra Nora Gonzalez-Diaz
MSMario Sanchez-Borges
Mario Sanchez-Borges
DRDiana Maria Rangel-Gonzalez
Diana Maria Rangel-Gonzalez
RGRosa Ivett Guzman-Avilan
Rosa Ivett Guzman-Avilan
JCJose Ignacio Canseco-Villarreal
Jose Ignacio Canseco-Villarreal
AAAlfredo Arias-Cruz
Alfredo Arias-Cruz
Urticaria is defined as the sudden appearance of erythematous, itchy wheals of variable size, with or without angioedema (AE) (swelling of the deeper layers of the skin). Its classification depends on time course of symptoms and the presence of eliciting factors. When it lasts less than 6 weeks it is classified as acute urticaria (AU), and if the symptoms persist for more than 6 weeks, it is classified as chronic urticaria (CU). Current International Guidelines also classify CU as chronic spontaneous urticaria (CSU) and inducible urticarial, according to the absence or presence of environmental triggering factors. CSU is defined as urticaria and/or angioedema in which there is no evidence of a specific eliciting factor. CSU is associated with autoimmunity in 30-45% of the cases, sharing some immunological mechanisms with other autoimmune diseases, and is associated with autoimmune thyroid disease (ATD) in about 4.3%-57.4% patients. Several studies suggest that adequate therapy with anti-thyroid drugs or levothyroxine in early stages of ATD and CSU, may help to remit the latter; but there is still a lack of double-blind, placebo-controlled studies that support this hypothesis in patients without abnormal thyroid hormone levels. The objective of this review is to describe the pathophysiology of chronic spontaneous urticaria and its association with autoimmune thyroid disease.

1 January 2017 in World Allergy Organization Journal
Verified
Journal Article
Open access
PDF file
SGSandra Nora González-Díaz
Sandra Nora González-Díaz
AAAlfredo Arias-Cruz
Alfredo Arias-Cruz
BEBárbara Elizondo-Villarreal
Bárbara Elizondo-Villarreal
OMOlga Patricia Monge-Ortega
Olga Patricia Monge-Ortega
Psychoneuroimmunoendocrinology, which was first described in 1936, is the study of the interactions between the psyche, neural and endocrine functions and immune responses. The aim of psychoneuroimmunoendocrinology is to apply medical knowledge to the treatment of different allergic, immune, autoimmune, rheumatic, neoplastic, endocrine, cardiovascular and dental pathologies, among other disorders. Epigenetic factors and major stresses from different types of stimuli acting through distinct pathways and neurotransmitters are highly involved in altering the psychoneuroimmunoendocrine axis, resulting in the emergence of disease. The main purpose of this report is to expand the understanding of psychoneuroimmunoendocrinology and to demonstrate the importance of the above-mentioned interactions in the etiology of multiple pathologies. In this review, a search of the medical literature using PubMed (free access search engine for the Medline database of the National Library of Medicine of the United States) over the years 1936 to 2016 was conducted, and descriptive and experimental studies and reviews of the scientific literature were included.

1 January 2014 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
AMAlexandra Michels
Alexandra Michels
HDHanna Dinger
Hanna Dinger
KSKija Shah-Hosseini
Kija Shah-Hosseini
Ralph MösgesRalph Mösges
Ralph Mösges
PRPablo G Rodríguez‐Ortiz
Pablo G Rodríguez‐Ortiz
Background: Allergen exposure leads to allergen sensitization in susceptible individuals and this might influence allergic rhinitis (AR) phenotype expression. We investigated whether sensitization patterns vary in a country with subtropical and tropical regions and if sensitization patterns relate to AR phenotypes or age.Methods: In a national, cross‐sectional study AR patients (2‐70 y) seen by allergists underwent blinded skin prick testing with a panel of 18 allergens and completed a validated questionnaire on AR phenotypes.Results: 628 patients were recruited. The major sensitizing allergen was house dust mite (HDM) (56%), followed by Bermuda grass (26%), ash (24%), oak (23%) and mesquite (21%) pollen, cat (22%) and cockroach (21%). Patients living in the tropical region were almost exclusively sensitized to HDM (87%). In the central agricultural zones sensitization is primarily to grass and tree pollen. Nationwide, most study subjects had perennial (82.2%), intermittent (56.5%) and moderate‐severe (84.7%) AR. Sensitization was not related to the intermittent‐persistent AR classification or to AR severity; seasonal AR was associated with tree (p < 0.05) and grass pollen sensitization (p < 0.01). HDM sensitization was more frequent in children (0‐11 y) and adolescents (12‐17 y) (subtropical region: p < 0.0005; tropical region p < 0.05), but pollen sensitization becomes more important in the adult patients visiting allergists (Adults vs children + adolescents for tree pollen: p < 0.0001, weeds: p < 0.0005).Conclusions: In a country with (sub)tropical climate zones SPT sensitization patterns varied according to climatological zones; they were different from those found in Europe, HDM sensitization far outweighing pollen allergies and Bermuda grass and Ash pollen being the main grass and tree allergens, respectively. Pollen sensitization was related to SAR, but no relation between sensitization and intermittent‐persistent AR or AR severity could be detected. Sensitization patterns vary with age (child HDM, adult pollen). Clinical implications of our findings are dual: only a few allergens –some region specific‐ cover the majority of sensitizations in (sub)tropical climate zones. This is of major importance for allergen manufacturers and immunotherapy planning. Secondly, patient selection in clinical trials should be based on the intermittent‐persistent and severity classifications, rather than on the seasonal‐perennial AR subtypes, especially when conducted in (sub)tropical countries.

1 November 2020 in World Allergy Organization Journal
Verified
Journal Article
Open access
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
NRNoel Rodríguez-Pérez
Noel Rodríguez-Pérez
AAAlfredo Arias-Cruz
Alfredo Arias-Cruz
MBMaría Virginia Blandón-Vijil
María Virginia Blandón-Vijil
BRBlanca Estela Del Rio-Navarro
Blanca Estela Del Rio-Navarro
MRMaría Isabel Rojo-Gutiérrez
María Isabel Rojo-Gutiérrez
In the light of the current COVID-19 pandemic, during which the world is confronted with a new, highly contagious virus that suppresses innate immunity as one of its initial virulence mechanisms, thus escaping from the first-line human defense mechanisms, enhancing innate immunity seems a good preventive strategy. Without the intention to write an official systematic review, but more to give an overview of possible strategies, in this review article we discuss several interventions that might stimulate innate immunity and thus our defense against (viral) respiratory tract infections. Some of these interventions can also stimulate the adaptive T- and B-cell responses, but our main focus is on the innate part of immunity. We divide the reviewed interventions in: 1) lifestyle related (exercise, >7 hours sleep, forest walking, meditation/mindfulness, vitamin supplementation); 2) Non-specific immune stimulants (letting fever advance, bacterial vaccines, probiotics, dialyzable leukocyte extract, pidotimod) and 3) specific vaccines with heterologous effect (BCG vaccine, mumps-measles-rubeola vaccine, i.e.). For each of these interventions we briefly comment on their definition, possible mechanisms and evidence of clinical efficacy or lack of it, especially focusing on respiratory tract infections, viral infections and eventually a reduced mortality in severe respiratory infections in the intensive care unit. At the end a summary table demonstrates the best trials supporting (or not) clinical evidence. Several interventions have some degree of evidence for enhancing the innate immune response and thus conveying possible benefit, but specific trials in COVID-19 should be conducted to support solid recommendations.

1 September 2014 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
EJEdgardo José Jares
Edgardo José Jares
MSMario Sánchez-Borges
Mario Sánchez-Borges
RCRicardo Cardona-Villa
Ricardo Cardona-Villa
LELUIS FELIPE ENSINA
LUIS FELIPE ENSINA
AAAlfredo Arias-Cruz
Alfredo Arias-Cruz
ICIvan Chérrez-Ojeda
Ivan Chérrez-Ojeda